Odyssey Health hires CCO and COO for NeuroPharma; salaries contingent on $5M fundraising

Odyssey Health, Inc.

Erik Emerson named CCO and Greg Gironda named COO of Odyssey NeuroPharma, effective Nov 1, 2022.
Each receives one-year term at 33% part-time commitment; base salary of $125K payable only after company raises $5M.
Each granted 600K stock options: 125K vest on signing, 300K upon $5M+ financing, 175K upon Nasdaq/NYSE listing.
Executives bring over 50 years combined pharmaceutical commercialization experience.
Odyssey aims to advance concussion and Niemann-Pick treatments through Phase II trials.

item 1.01 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Greg Gironda

Chief Operations Officer

ODYY · Odyssey Health, Inc.

Effective: 2022-11-01
Filed: November 4, 2022, 7:59 PM ET

On November 1, 2022, the Company and Mr. Gironda entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Operations Officer.

Appointed

Erik Emerson

Chief Commercial Officer

ODYY · Odyssey Health, Inc.

Effective: 2022-11-01
Filed: November 4, 2022, 7:59 PM ET

On November 1, 2022, the Company and Mr. Emerson entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Commercial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Greg Gironda was appointed as Chief Operations Officer at Odyssey Health, Inc..

Action: appointed
Role: Chief Operations Officer

Exact text from the filing

On November 1, 2022, the Company and Mr. Gironda entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Operations Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Erik Emerson was appointed as Chief Commercial Officer at Odyssey Health, Inc..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On November 1, 2022, the Company and Mr. Emerson entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Commercial Officer.

View on SEC.gov

Odyssey Health, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-007279

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.